Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04601129
Other study ID # 2019_21
Secondary ID 2019-A02271-56
Status Recruiting
Phase
First received
Last updated
Start date August 1, 2020
Est. completion date December 2023

Study information

Verified date February 2023
Source University Hospital, Lille
Contact Gilles Lebuffe, MD,PhD
Phone 03 20 44 45 08
Email gilles.lebuffe@chru-lille.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Shorten the time spent in the hospital (hospitalization duration) by optimizing the pre, per and postoperative care is of major medical and economic importance. Minimally invasive surgery allows a faster recovery than open surgery. However, we need to ensure an early and secure return to normality in order to discharge patients safely from the hospital. Clinical and biological parameters need to be controlled post-surgery. This work is going to evaluate the efficacity of a fast - recovery program with incoming patients receiving minimally invasive surgery (laparoscopic or robotic) of partial and total nephrectomy. The implementation of a medical and surgical fast-recovery program could - Lower the average duration of stay in hospital (at least by 1 day) with no increase of morbidity - Insure the absence of complications after 6 months home


Description:

Prospective study of a fast recovery program evaluating the impact on the hospitalization length and the incidence of re-hospitalization for complications for 60 patients undergoing a minimally invasive nephrectomy. The cohort will beneficiate of an extra preoperative information about the enhanced recovery after surgery program, they will benefit from a strategie of low morphine consumption during the per end post operative phase, they should need no bladder or abdominal drainage, they're encourage to eat and drink a few hours after surgery, the intravenous fluid is interrupted as early as possible, and the patients are encourage to sit, stand up and get dressed as soon as they are capable. A form completed by the patient registers their every day capabilities to eat, drink, move, and their limitations due to pain, dizziness, and nausea. Their bowel and urine transit are also registered. This form is complete until discharge from the hospital. Their laboratory test is monitored to identify kidney insufficiency or anemia and compared with the preoperative laboratory tests. The hospital discharge is allowed after medical and surgical criteria are met in both groups. A surgical evaluation is planned a week, one month, and 6 months after surgery with laboratory exams. 1 month after the discharge, a satisfaction questionnaire is filled up by the patient, answered by telephone. At the 6 months post operative consultation, a questionnaire about chronic pain is submitted. If the patient is eligible, a chronic pain consultation is further organized. The result will be compared to those of a retrospective cohort (+/- 60 patients) with no enhanced recovery after surgery program.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date December 2023
Est. primary completion date December 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Patient score from the American Society of Anesthesiologist (ASA) I, II or III stable - Patients undergoing minimally invasive surgery (laparoscopic or robotic) partial or total unilateral nephrectomies for tumoral < pT2 stage (7 cm) with no tumor spread of the retro-peritoneal tissue, vascular or urinary tract. - Surgery must be performed by a laparoscopic and robotic-assisted surgeon, operator must be trained using these techniques Exclusion Criteria: - Patient score from the American Society of Anesthesiologist (ASA) III unstable, IV and V - Patients with renal insufficiency defined by clearance < 60 ml/min/1,73m2 (CKD-EPI) - Patients with high embolic risk under long-term anti-coagulation medication - Patients with congenital hemostatic deficit or antiplatelet treatment - Patients with long term corticosteroids treatments - History of kidney surgery or congenital unique kidney - History of multiple abdominal surgery creating a hostile surgical environment - intestinal chronic disease or chronic pain syndrome - Psychiatric disorder, cognitive impairment reducing the ability to understand the discharge instructions - Pregnant or breast-feeding women - Patients with no social security covers

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
enhanced recovery after surgery program
practice of an enhanced recovery after surgery program, according to the international reviews of literature and national recommendation

Locations

Country Name City State
France Hop Claude Huriez Chu Lille Lille

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Lille

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Length of hospital stay at 1 month
Secondary Hospital readmission rate at 1 month post surgery at 1 month
Secondary Postoperative antalgic consumption in Enhanced recovery after surgery patients through the hospitalization, up to 5 days post surgery and long term, average of 6 months post surgery
Secondary Preoperative and postoperative Creatinine and Clearance of creatinine Delta by the CKD-EPI formula Baseline, at 24 hours, at 1 week and at 6 months
Secondary Average Satisfaction of hospital stay and discharge on a satisfaction numerical scale Satisfaction numerical scale from 0 to 10 : with 0 being the least satisfied possible to 0 being the most satisfied possible at 1 month post surgery
Secondary Neuropathic pain by Douleur Neuropathique 4 (DN4) questionnaire. The questionnaire is made of 10 binnaire questions with "yes" or "no" answers, yes standing for 1 point, no standing for 0 point. The minimum score is 0 reflecting the absence of neuropathic pain, the maximum score is 10 reflecting the most intense neuropathic pain possible. The test is positive for the diagnosis of post surgical neuropathic pain at a score of 4 and above. 3 and 6 months post surgery
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04987203 - Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Phase 3
Recruiting NCT06391879 - Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Terminated NCT03655613 - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC Phase 1/Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Withdrawn NCT05418387 - A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona N/A
Recruiting NCT04623502 - An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy N/A
Completed NCT02853344 - Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427) Phase 2
Terminated NCT04088500 - A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma Phase 2
Completed NCT05070637 - Circulating Tumor Cell Reducing No-touch Nephrectomy N/A
Active, not recruiting NCT03634540 - A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) Phase 2
Not yet recruiting NCT06049030 - A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma Phase 1
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT01358721 - Phase I Biomarker Study (BMS-936558) Phase 1
Active, not recruiting NCT04503148 - Anesthesia and Cancer Study: Renal Cell Carcinoma N/A
Completed NCT02386826 - INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme Phase 1
Not yet recruiting NCT05808608 - A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma Phase 1/Phase 2
Withdrawn NCT03323710 - Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma Phase 2
Not yet recruiting NCT02787915 - DC1s-CTL Cellular Therapy for Renal Cell Carcinoma Phase 1/Phase 2